MEI Pharma (NASDAQ:MEIP) and Japan's Kyowa Kirin (OTCPK:KYKOF) on Monday said they would end global development of investigational cancer treatment zandelisib outside of Japan for B-cell malignancies. The decision to discontinue development came after the companies received guidance from a late Nov. meeting with the U.S. FDA. "Following the November meeting, the companies concluded that a clinical trial consistent with the recent FDA guidance, including modification of the COASTAL trial, would likely not be feasible to complete within a time period that would support further investment," MEIP and KYKOF said in a statement. "In light of FDA’s guidance, we no longer believe clinical development can be completed within a time period that would support further investment, or with sufficient certainty of the regulatory requirements to justify continued global development efforts," MEIP CEO Daniel Gold commented. MEIP also separately announced a strategic realignment, including a workforce reduction.